This presentation contains forward-looking statements, including statements concerning anticipated clinical development activities, the potential benefits of product candidates and anticipated market opportunities. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals, and the risk factors set forth in the company’s filings with the CSE & OTCQB. The company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.
Overview

- InMed is a publically listed Vancouver-based biopharmaceutical company focused identifying, developing and commercializing prescription drugs using **non-THC** cannabinoids - extensive physiologic effects, limited safety concerns.

- Proprietary drug/target bioinformatics screening process
- Proprietary cannabinoid biosynthesis manufacturing system

- Targeting high unmet medical conditions utilizing disease-specific formulations:
  - Epidermolysis Bullosa – An orphan pediatric disease characterized by extremely fragile skin with no current approved therapies. Potential of ~$1B.
  - Glaucoma – A serious eye disease with a global market of >$5B.

- Intellectual property platform providing protection for its clinical candidates

- Listing on the **OTCQB:IMLFF** and the **CSE:IN**
Experienced Management Team

**Eric A. Adams – CEO + President**
- 25+ years’ experience in global biopharmaceutical business development, S&M, M&A
- Capital formation, drug development, partnering/licensing of assets, mentorship of start-ups
- enGene, QLT, Advanced Tissue Sciences, Abbott Laboratories, Fresenius AG

**Dr. Sazzad Hossain, PhD, MSc - Chief Scientific Officer, Co-Founder**
- 20+ years of academic/industrial experience in drug discovery and product development
- Associate Director of Pharmacology at Xenon Pharmaceuticals where he led pharmacology teams targeting pain, inflammation and cardiovascular diseases
- Group Leader and Senior Scientist at Biotechnology Research Institute of National Research Council Canada, Government of Canada’s prime biotechnology research center
- PhD in Biology with post doctoral training in the Department of Nutritional Science and Department of Medical Genetics of UBC; Associate Professor of Pharmacology at Federal University of Minas Gerais, Brazil.

**Dr. Ado Mohammed, MD, DPM, MFPM – Chief Medical Officer**
- Associate Medical Director at GW Pharmaceuticals, a UK-based Pharmaceutical Company specializing in the development of cannabinoid-based prescription medicines. In this role and others at GW Pharmaceuticals, Dr. Mohammed was involved in core clinical research and was in key decision-making regarding R&D and product commercialization.
Cannabinoids - a Rich Source of Therapeutics

- Cannabinoids interact with the body’s natural endogenous cannabinoid system (eCB), the body’s intrinsic system of cannabinoid molecules and receptors (CB1 And CB2) – effecting metabolism, inflammation, pain, cancer, neurotransmission and cognition.

- Biotech, Pharma and Investors actively engaged in Cannabinoid R&D
  - GW Pharma solely focused on cannabinoid development; market cap of >$2.3B on ~$50M revenues
  - 3 Cannabinoid products have been approved the US or Europe (Sativex™, Marinol™, Cesamet™); several pharma companies investing in R&D:

- The tolerability profile of cannabinoids is well characterized as safe; risk of clinical failure due to ADEs is reduced vis-à-vis small molecules.

- InMed cannabinoid drug development approach is differentiated by:
  - Novel mechanism for identifying therapeutic applications / Novel manufacturing process / Focus on high unmet medical needs
InMed’s proprietary drug discovery program utilizes a ‘systems approach’ to evaluate disease targets via our **proprietary bioinformatics algorithms**. Active compounds present in cannabinoids and non-cannabinoid plant sources are identified and selected by determining associations between approved pharmaceuticals and phytochemicals with similar structures, which are assessed *in vitro* and *in vivo* prior to selection for further development.
Proprietary Cannabinoid Biosynthesis in *E. coli*

Upstream and downstream cannabinoid synthesis pathways are integrated into a single pathway for the production of individual cannabinoids from glucose or glycerol.

Bioengineering of *E. coli*
1. Extraction, amplification and cloning
2. Chromosomal integration into cell

Biosynthesis of Cannabinoids
3. Scale-up and Systems Optimization
4. Production, Purification and QC
Lead Drug Development Programs

<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Discovery</th>
<th>Target Selection</th>
<th>Pre-Clinical, Formulation</th>
<th>Clinical Trials</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dermatology</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INM-750</td>
<td></td>
<td></td>
<td></td>
<td>2016</td>
</tr>
<tr>
<td>(Epidermolysis bullosa)</td>
<td></td>
<td></td>
<td></td>
<td>2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2018</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2019/20</td>
</tr>
<tr>
<td><strong>Ocular</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INM-085</td>
<td></td>
<td></td>
<td></td>
<td>2016</td>
</tr>
<tr>
<td>(Glaucoma)</td>
<td></td>
<td></td>
<td></td>
<td>*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
</tr>
<tr>
<td><strong>Other Diseases</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Dermatology** INM-750 (Epidermolysis bullosa)
  - EB patient population: ~25K in USA. Global market potential ~$1B
  - Timeline dependant on available capital. Partnership / spin-out opportunities.

- **Ocular** INM-085 (Glaucoma)
  - Glaucoma patient population: >2.7M in USA. Global market >$5.6B
  - Timeline dependant on available capital. Partnership / spin-out opportunities.

- **Other Diseases**
  - Timeline dependant on available capital. Partnership / spin-out opportunities.
Epidermolysis Bullosa (EB) is a group of inherited (genetic) connective tissue diseases that share a common manifestation of extremely fragile skin that blisters or tears easily. Human skin consists of two layers: an outermost layer called the epidermis, and a layer underneath called the dermis.

- There are protein (keratin) anchors between the two skin layers that prevent them from moving independently.
- In people born with EB, the two skin layers lack the protein anchors that hold them together, resulting in extremely fragile skin.
- Approximately 25K patients in the US, 500K WW
Epidermolysis Bullosa – Severe Symptoms and Poor Prognosis

No approved treatments for EB

InMed’s lead product, INM-750 targets CB1 and CB2 receptors in the skin to deliver symptomatic relief:
- accelerated wound healing
- pain reduction
- anti-itch properties
- antimicrobial activity
- anti-inflammation

AND may re-establish the epidermal/dermal junction by upregulation of specific keratins in the skin, essentially reversing the disease.
Acquisition of Scioderm by Amicus for $847M

- Scioderm’s sole clinical asset is Zorblisa™, a Ph3 product in development for EB
- Scioderm was acquired by Amicus in Sept ‘15 for US $847M ($229M upfront, $361M on clin/reg milestones, $257M on sales milestones)
  - Acquisition was based on results from 42 patients in a Ph2b study
- JP Morgan and Cowen research reports estimate peak sales for Zorblisa™ in EB of $900M - $1.2B

Acquisition of Lotus Tissue Repair by Shire for $174M

- Lotus Tissue Repair had a preclinical program developing recombinant human collagen Type VII ("rC7") as a protein replacement therapy for Dystrophic EB, a small subset (~5%) of the total EB population
- In February 2013 Shire acquired Lotus Tissue Repair for a fair value consideration totaled $174M: $49M upfront; fair value of contingent consideration of $125M.
Glaucoma – Serious Eye Disease Leading to Blindness

- Glaucoma is a group of eye disorders which result in damage of the optic nerve
- The damage is most often caused by an abnormally high pressure in the eye
- The most common form of glaucoma has no warning signs. The effect is so gradual that you may not notice a change in vision until the condition is at an advanced stage
- If the condition is detected early enough, it is possible to arrest the development or slow the progression by medical and surgical means
- 2nd leading cause of blindness in the developed world; >2.7M patients in US; $5.6B market WW
Currently, all approved treatments for glaucoma are based on a single MoA

INM-085 is a combination of cannabinoids selected to:

- Reduce the intraocular pressure (IOP) in the affected eyes; and
- Provide neuroprotection for the retinal ganglion cells (RGCs) and other optic nerve tissues.

- Unique delivery system: INM-085 utilizes a proprietary, temperature sensitive hydrogel formulation to address the major issues of non-compliance (side effects, dosing frequency and adherence).
  - Preclinical animal data showed enhanced penetration of cannabinoid molecules through the cornea and lens using this hydrogel formulation when compared to control.
INM-085 increases blood vessel diameter and reduces intraocular pressure after 30 minutes.
Investment Highlights

- **Extensive portfolio of assets** in dermatology, ocular diseases, additional indications as well as cannabinoid biosynthesis

- Set to **achieve value-driving, near-term milestones** with limited investment:
  - Lead drug candidate in an orphan pediatric disease with high unmet medical need; Completion of formulation development, toxicology and Ph1-2a clinical trials within 18 months from financing
  - Biosynthesis of cannabinoids commercial-ready within 24 months

- **Experienced team** capable of building value in biopharmaceuticals

- Compared to peers in the cannabinoid drug development and epidermolysis bullosa space, InMed is **substantially under-valued**
Board of Directors

• **William Garner, MD** - Founder of EGB Advisors PR LLC, a pharma commercialization boutique focused company development leading to monetization of assets via licensing, M&A or IPO. Currently Chairman/Founder of Race Oncology (ASX:RAC); Formerly Director +/- Executive at IGXBio; Invion Limited (ASX:IVX); Del Mar Pharma (NASDAQ: DMPI). Dr. Garner brings previous medical affairs experience (Hoffmann LaRoche) and healthcare merchant banking in NYC.


• **Adam Cutler** – 19+ years of experience in the global healthcare industry; senior leadership positions in Equity Research, Corporate Affairs and Strategy, Investor Relations and Consulting. Currently SVP of Corporate Affairs at Arbutus Biopharma; previously Managing Director at The Trout Group LLC. 12 years as a sell-side analyst with Credit Suisse, Canaccord Genuity, JMP Securities, BoA Securities, and analyst with The Frankel Group and E&Y Healthcare Consulting.

• **Craig Schneider, Co-Founder** – 20+ years of extensive experience in capital market financing, business development & strategic planning with public companies in Technology, Biotechnology and the Resource sector. He was a co-founder of Magnum Uranium, a TSX.V company which was purchased by Energy Fuels (TSX: EFR).

• **Eric A. Adams, President + CEO**
InMed Pharmaceuticals Inc.

#350-409 Granville Street, Vancouver, BC
Canada, V6C 1T2
Tel: +1.604.669.7207
Fax: +1.604.683.2506

www.inmedpharma.com

CSE:IN
OTCQB:IMLFF